ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

N4P N4 Pharma Plc

0.65
-0.025 (-3.70%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -3.70% 0.65 0.60 0.70 0.675 0.625 0.675 1,668,891 16:20:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 0 -1.03M -0.0057 -1.14 1.18M

N4 Pharma PLC Change of Adviser (9917S)

15/07/2020 7:00am

UK Regulatory


N4 Pharma (LSE:N4P)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more N4 Pharma Charts.

TIDMN4P

RNS Number : 9917S

N4 Pharma PLC

15 July 2020

15 July 2020

N4 Pharma plc

("N4 Pharma" or the "Company")

Change of Adviser

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce the appointment of SP Angel Corporate Finance LLP as the Company's Nominated Adviser and Joint Broker, with immediate effect.

Management Change

The Company also announces that Luke Cairns, previously a Non-Executive Director of the Company, has been appointed to an Executive Director position. Luke will be overseeing the Company's finance and investor relations activities, thereby allowing Nigel Theobald, Chief Executive Officer, more time to focus on driving the Company's development programmes and potential commercial collaborations.

Enquiries:

 
 N4 Pharma plc 
 Nigel Theobald, CEO                        Via Scott PR 
 Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP             Tel: +44(0)20 3470 
                                             0470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
 Vadim Alexandre/Abigail Wayne/Rob Rees 
  (Corporate Broking) 
 
 Turner Pope Investments (TPI) Limited      Tel: +44(0)20 3657 
                                             0050 
 Joint Broker 
 Andy Thacker 
 
 Scott PR 
 Georgia Smith                              Tel: +44(0)1477 539 
                                             539 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPRIMITMTJBBMM

(END) Dow Jones Newswires

July 15, 2020 02:00 ET (06:00 GMT)

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Your Recent History

Delayed Upgrade Clock